Eli Lilly has entered into an agreement to gain an exclusive worldwide license for a portfolio of programs from Insilico Medicine, including several novel oral therapeutics in preclinical development.
The license gives Lilly development, manufacturing, and commercialization rights for what have the potential to be best-in-class medications for various indications in numerous therapeutic areas. Lilly is also choosing targets for R&D programs that will use Insilico’s Pharma.AI platform. The companies announced back in November that Insilico would be utilitizing its platform along with its knowledge of deep drug discovery to generate, design, and optimize compounds for these targets.
Insilico will receive an upfront payment of $115 million in a deal that may be worth a total of around $2.75 billion in development, regulatory, and commercial milestones. Insilico will also receive tiered royalties on future sales.